your market intelligence analyst
Search Results
35 results
Your search is now limited to «Pancreatic Cancer» expert search.
PR Newswire 10/22/2019 11:19
BARCELONE, 22 octobre 2019 /PRNewswire/ -- Les résultats d'une importante étude réalisée dans 195 pays, présentés aujourd'hui à l'UEG Week Barcelona 2019, indique que les taux de décès mondiaux du cancer du pancréas et les taux d'incidence du cancer colorectal ont baissé de 10 % entre...
American Diabetes Journals 10/21/2019 15:00
OBJECTIVE. Dipeptidyl peptidase 4 inhibitors (DPP-4i) are useful incretin-based antidiabetes drugs. However, there is a concern that DPP-4i may adversely impact the exocrine pancreas, owing to their pleiotropic effects. In this study, we investigated whether DPP-4i are associated with pancreatitis and pancreatic cancer using a nationwide population-based cohort study. RESEARCH DESIGN AND METHODS. We included patients newly diagnosed with type 2 diabetes who were treated with antidiabetes drugs ( n = 33,208) from 2007 to 2013. The data were obtained from the Korean National Health Insurance Service–Health Screening Cohort database ( n = 514,866). Risk was estimated using a Cox proportional hazards model with time-dependent covariates. A 6-mont.
Onclive 10/17/2019 13:37
The addition of cisplatin to gemcitabine and nab-paclitaxel resulted in encouraging activity in patients with previously untreated advanced pancreatic cancer, despite not having demonstrated the prespecified number of complete responses to meet the primary endpoint of a phase Ib/II clinical trial (NCT01893801), according to findings published in JAMA Oncology .

Automotive Industries

Business Issues

Companies - Public

Companies - Venture Funded

Global Markets

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Market Research Topics

Political Entities


Strategic Scenarios